ANKK1 and DRD2 pharmacogenetics of disulfiram treatment for cocaine abuse

Pharmacogenetics and Genomics

Volumn 23, Issue 7, 2013, Pages 333-340

  Spellicy, Catherine J ^a   Kosten, Thomas R ^a   Hamon, Sara C ^b   Harding, Mark J ^a   Nielsen, David A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Ankyrin Repeat And Kinase Domain Containing 1; Cocaine; Dependence; Disulfiram; Dopamine Receptor D2; Treatment

Indexed keywords

ANKYRIN; DISULFIRAM; DOPAMINE 2 RECEPTOR; KINASE DOMAIN CONTAINING 1; METHADONE; PLACEBO; PROTEIN KINASE; UNCLASSIFIED DRUG;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CLINICAL ARTICLE; COCAINE DEPENDENCE; COGNITIVE THERAPY; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG ABUSE; DSM-IV; FEMALE; GENE INTERACTION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MALE; METHADONE TREATMENT; PHARMACOGENETICS; POPULATION STRUCTURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; URINALYSIS;

EID: 84879158886     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e328361c39d     Document Type: Article

References (69)

1. SAMHSA. Results from the 2010 National Survey on Drug Use and Health (NSDUH), N.S. H-41, Editor. Rockville, MD: SAMHSA; 2011.
2. McLellan AT, Lewis DC, O'Brien CP, Kleber HD. Drug dependence, a chronic medical illness: Implications for treatment, insurance, and outcomes evaluation. JAMA 2000; 284:1689-1695.
3. Wolf BC, Lavezzi WA, Sullivan LM, Flannagan LM. Methadone-related deaths in Palm Beach County. J Forensic Sci 2004; 49:375-378.
4. Bux DA, Lamb RJ, Iguchi MY. Cocaine use and HIV risk behavior in methadone maintenance patients. Drug Alcohol Depend 1995; 37:29-35.
5. MacGowan RJ, Fichtner RR, Swanson N, Collier C, Kroliczak A, Cole G. Factors associated with client-reported HIV infection among clients entering methadone treatment. AIDS Educ Prev 1997; 9:205-217.
6. Meandzija B, O'Connor PG, Fitzgerald B, Rounsaville BJ, Kosten TR. HIV infection and cocaine use in methadone maintained and untreated intravenous drug users. Drug Alcohol Depend 1994; 36:109-113.
7. Hartel DM, Schoenbaum EE, Selwyn PA, Kline J, Davenny K, Klein RS, Friedland GH. Heroin use during methadone maintenance treatment: The importance of methadone dose and cocaine use. Am J Public Health 1995; 85:83-88.
8. Bovasso G, Cacciola J. The long-term outcomes of drug use by methadone maintenance patients. J Behav Health Serv Res 2003; 30:290-303.
9. Kosten TR, Rounsaville BJ, Kleber HD. Antecedents and consequences of cocaine abuse among opioid addicts. A 2.5-year follow-up. J Nerv Ment Dis 1988; 176:176-181.
10. Magura S, Rosenblum A, Rodriguez EM. Changes in HIV risk behaviors among cocaine-using methadone patients. J Addict Dis 1998; 17:71-90.
11. Magura S, Rosenblum A, Fong C, Villano C, Richman B. Treating cocaineusing methadone patients: Predictors of outcomes in a psychosocial clinical trial. Subst Use Misuse 2002; 37:1927-1955.
12. Black JL, Dolan MP, Penk WE, Robinowitz R, DeFord HA. The effect of increased cocaine use on drug treatment. Addict Behav 1987; 12:289-292.
13. Dunteman GH, Condelli WS, Fairbank JA. Predicting cocaine use among methadone patients: Analysis of findings from a national study. Hosp Community Psychiatry 1992; 43:608-611.
14. Lima MS, Reisser AA, Soares BG, Farrell M. Antidepressants for cocaine dependence. Cochrane Database Syst Rev 2003; 2:CD002950.
15. Lima AR, Lima MS, Soares BG, Farrell M. Carbamazepine for cocaine dependence. Cochrane Database Syst Rev 2002; 2:CD002023.
16. Carroll KM, Fenton LR, Ball SA, Nich C, Frankforter TL, Shi J, Rounsaville BJ. Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: A randomized placebo-controlled trial. Arch Gen Psychiatry 2004; 61:264-272.
17. Carroll KM, Nich C, Ball SA, McCance E, Rounsavile BJ. Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction 1998; 93:713-727.
18. Carroll KM. Psychotherapeutic treatment of cocaine abuse: Models for its evaluation alone and in combination with pharmacotherapy. NIDA Res Monogr 1993; 135:116-132.
19. George TP, Chawarski MC, Pakes J, Carroll KM, Kosten TR, Schottenfeld RS. Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: A preliminary trial. Biol Psychiatry 2000; 47:1080-1086.
20. Petrakis IL, Carroll KM, Nich C, Gordon LT, McCance-Katz EF, Frankforter T, Rounsaville BJ. Disulfiram treatment for cocaine dependence in methadonemaintained opioid addicts. Addiction 2000; 95:219-228.
21. Vaccari A, Saba PL, Ruiu S, Collu M, Devoto P. Disulfiram and diethyldithiocarbamate intoxication affects the storage and release of striatal dopamine. Toxicol Appl Pharmacol 1996; 139:102-108.
22. Johnson SM, Fleming WW. Mechanisms of cellular adaptive sensitivity changes: Applications to opioid tolerance and dependence. Pharmacol Rev 1989; 41:435-488.
23. Bourdelat-Parks BN, Anderson GM, Donaldson ZR,Weiss JM, Bonsall RW, Emery MS, et al. Effects of dopamine beta-hydroxylase genotype and disulfiram inhibition on catecholamine homeostasis in mice. Psychopharmacology (Berl) 2005; 183:72-80.
24. Schank JR, Ventura R, Puglisi-Allegra S, Alcaro A, Cole CD, Liles LC, et al. Dopamine beta-hydroxylase knockout mice have alterations in dopamine signaling and are hypersensitive to cocaine. Neuropsychopharmacology 2006; 31:2221-2230.
25. Goldman D, Oroszi G, Ducci F. The genetics of addictions: Uncovering the genes. Nat Rev Genet 2005; 6:521-532.
26. Leshner AI. Addiction is a brain disease, and it matters. Science 1997; 278:45-47.
27. Weisner C, Matzger H, Kaskutas LA. How important is treatment? One-year outcomes of treated and untreated alcohol-dependent individuals. Addiction 2003; 98:901-911.
28. Simpson DD, Joe GW, Broome KM. A national 5-year follow-up of treatment outcomes for cocaine dependence. Arch Gen Psychiatry 2002; 59: 538-565.
29. Sofuoglu M, Kosten TR. Emerging pharmacological strategies in the fight against cocaine addiction. Expert Opin Investig Drugs 2006; 11:91-98.
30. Kosten TR, Wu G, Huang W, Harding MJ, Hamon SC, Lappalainen J, Nielsen DA. Pharmacogenetic randomized trial for cocaine abuse: Disulfiram and dopamine beta-hydroxylase. Biol Psychiatry 2013; 73:219-224.
31. McAllister T, Flashman L, Rhodes C, Tyler A, Moore J, Saykin A, et al. Single nucleotide polymorphisms in ANKK1 and the dopamine D2 receptor gene affect cognitive outcome shortly after traumatic brain injury: A replication and extension study. Brain Inj 2008; 22:705-714.
32. Giegling I, Balzarro B, Porcelli S, Schafer M, Hartmann AM, Friedl M, et al. Influence of ANKK1 and DRD2 polymorphisms in response to haloperidol. Eur Arch Psychiatry Clin Neurosci 2013; 263:65-74.
33. Yang B, Kranzler H, Zhao H, Gruen J, Luo X, Gelernter J. Association of haplotypic variants in DRD2, ANKK1, TTC12 and NCAM1 to alcohol dependence in independent case control and family samples. Hum Mol Genet 2007; 16:2844-2853.
34. Yang B, Kranzler H, Zhao H, Gruen J, Luo X, Gelernter J. Haplotypic variants in DRD2, ANKK1, TTC12 and NCAM1 are associated with comorbid alcohol and drug dependence. Alcohol Clin Exp Res 2008; 32:2117-2127.
35. Golimbet V, Aksenova M, Nosikov V, Orlova V, Kaleda V. Analysis of the linkage of the Taq1A and Taq1B loci of the dopamine D2 receptor gene with schizophrenia in patients and their siblings. Neurosci Behav Physiol 2003; 33:223-225.
36. Glatt S, Faraone S, Lasky-Su J, Kanazawa T, Tsuang M. Family-based association testing strongly implicates DRD2 as a risk gene for schizophrenia in Han Chinese from Taiwan. Mol Psychiatry 2009; 14:885-893.
37. Comings D, Comings B, Muhleman D, Dietz G, Shahbahrami B, Tast D, et al. The dopamine D2 receptor locus as a modifying gene in neuropsychiatric disorders. JAMA 1991; 266:1793-1800.
38. Voisey J, Swagell C, Hughes I, van Daal A, Noble E, Lawford B, et al. A DRD2 and ANKK1 haplotype is associated with nicotine dependence. Psychiatry Res 2012; 196:285-289.
39. Blum K, Noble E, Sheridan P, Finley O, Montgomery A, Ritchie T, et al. Association of the A1 allele of the D2 dopamine receptor gene with severe alcoholism. Alcohol 1991; 8:409-416.
40. Blum K, Noble E, Sheridan P, Montgomery A, Ritchie T, Jagadeeswaran P, et al. Allelic association of human dopamine D2 receptor gene in alcoholism. JAMA 1990; 26:2055-2060.
41. Connor J, Young R, Lawford B, Saunders J, Ritchie T, Noble E. Heavy nicotine and alcohol use in alcohol dependence is associated with D2 dopamine receptor (DRD2). Addict Behav 2007; 32:310-319.
42. Noble E. Polymorphisms of the D2 dopamine receptor gene and alcoholism and other substance use disorders. Alcohol Alcohol Suppl 1994; 2:35-43.
43. Noble E, Blum K, Ritchie T, Montgomery A, Sheridan P. Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Arch Gen Psychiatry 1991; 48:648-654.
44. Zhang Y, Bertolino A, Fazio L, Blasi G, Rampino A, Romano R, et al. Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory. Proc Natl Acad Sci USA 2007; 104:20552-20557.
45. Moyer R, Wang D, Papp A, Mith RS, Duque L, Mash D, Sadee W. Intronic polymorphisms affecting alternative splicing of human dopamine D2 receptor are associated with cocaine abuse. Neuropsychopharmacology 2011; 36:753-762.
46. Jonsson E, Nothen M, Grunhage F, Farde L, Nakashima Y, Propping P, Sedvall G. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry 1999; 4:290-296.
47. Hoenicka J, Qunones-Lombrana A, Espana-Serrano L, Alvira-Botero X, Kremer L, Perez-Gonzalez R, et al. The ANKK1 gene associated with addictions is expressed in astroglial cells and upregulated by apomorphine. Biol Psychiatry 2010; 67:3-11.
48. Dubertret C, Gorwood P, Gouya L, Deybach J, Ades J. Association and excess of transmission of a DRD2 haplotype in a sample of French schizophrenic patients. Schizophr Res 2001; 49:203-212.
49. Noble E, Blum K, Khalsa M, Ritchie T, Montgomery A, Wood R, et al. Allelic association of the D2 dopamine receptor gene with cocaine dependence. Drug Alcohol Depend 1993; 33:271-285.
50. McLellan A, Kushner H, Metzger D, Peters R, Grissom G, Pettinati H, Argeriou M. The Fifth Edition of the Addiction Severity Index. J Subst Abuse Treat 1992; 9:199-213.
51. Sheehan D, Lecrubier Y, Sheehan K, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59:22-33.
52. Carroll KM. Manual-guided psychosocial treatment. A new virtual requirement for pharmacotherapy trials? Arch Gen Psychiatry 1997; 54: 923-928.
53. Nielsen DA, Harding MJ, Hamon SC, Huang W, Kosten TR. Modifying the role of serotonergic 5-HTTLPR and TPH2 variants on disulfiram treatment of cocaine addiction: A preliminary study. Genes Brain Behav 2012; 11: 1001-1008.
54. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2009.
55. Comings D, Rosenthal R, Lesieur H, Rugle L, Muhleman D, Chiu C, et al. A study of the dopamine D2 receptor gene in pathological gambling. Pharmacogenetics 1996; 6:223-234.
56. Persico A, Bird G, Gabbay F, Uhl G. D2 dopamine receptor gene TaqI A1 and B1 restriction fragment length polymorphisms: Enhanced frequencies in psychostimulant-preferring polysubstance abusers. Biol Psychiatry 1996; 40:776-784.
57. Lawford B, Young R, Noble E, Sargent J, Rowell J, Shadforth S, et al. The D(2) dopamine receptor A(1) allele and opioid dependence: Association with heroin use and response to methadone treatment. Am J Med Genet 2000; 96:592-598.
58. Munafo M, Clark T, Johnstone E, Murphy M,Walton R. The genetic basis for smoking behavior: A systematic review and meta-analysis. Nicotine Tob Res 2004; 6:583-597.
59. Perez de los Cobos J, Baiget M, Trujols J, Sinol N, Volpini V, Banuls E, et al. Allelic and genotypic associations of DRD2 TaqI A polymorphism with heroin dependence in Spanish subjects: A case control study. Behav Brain Funct 2007; 3:25.
60. Denys D, Nieuwerburgh FV, Deforce D,Westenberg H. Association between the dopamine D2 receptor TaqIA A2 allele and low activity COMT allele with obsessive-compulsive disorder in males. Eur Neuropsychopharmacol 2006; 16:446-450.
61. Nisoli E, Comings B, Muhleman D, Dietz G, Shahbahrami B, Tast D, et al. D2 dopamine receptor (DRD2) gene Taq1A polymorphism and the eating-related psychological traits in eating disorders (anorexia nervosa and bulimia) and obesity. Eat Weight Disord 2007; 12:91-96.
62. Neville M, Johnstone E, RT W. Identification and characterization of ANKK1: A novel kinase gene closely linked to DRD2 on chromosome band 11p23.1. Hum Mutat 2004; 23:540-545.
63. Khan Z, Mrzlijak L, GUtierrez A, de la Calle A, Goldman-RAkic P. Prominence of the dopamine D2 short isoform in dopaminergic pathways. Proc Natl Acad Sci USA 1998; 95:7731-7736.
64. Nader M, Morgan D, Gage H, Nader S, Calhoun T, Buchheimer N, et al. PET imaging of dopamine D2 receptors during chronic cocaine selfadministration in monkeys. Nat Neurosci 2006; 9:1050-1056.
65. Thompson J, Thomas N, Singleton A, Piggott M, Lloyd S, Perry E, et al. D2 dopamine receptor gene (DRD2) Taq1A polymorphism: Reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 1997; 7:479-484.
66. Ritchie T, Noble E. Association of seven polymorphisms of the D2 dopamine receptor gene with brain receptor-binding characteristics. Neurochem Res 2003; 28:73-82.
67. Pohjalainen T, Rinne J, Nagren K, Lehikoinen P. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol Psychiatry 1998; 3:256-260.
68. Dick D, Wang J, Plunkett J, Aliev F, Hinrichs A, Bertelsen S, et al. Familybased association analyses of alcohol dependence phenotypes across DRD1 and neighboring gene ANKK1. Alcohol Clin Exp Res 2007; 31: 1645-1653.
69. Gelernter J, Yu Y, Weiss R, Brady K, Panhuysen P, Yang B, et al. Haplotype spanning TTC12 and ANKK1, flanked by the DRD2 and NCAM1 loci, is strongly associated to nicotine dependence in two distinct American populations. Hum Mol Genet 2006; 15:3498-3507.